Editorial
Can CT radiomics differentiate benign from malignant N2 adenopathy in non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(5)
:1710-1711
.
(28 October 2020)
On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
Translational Lung Cancer Research
2020;
9
(5)
:1712-1719
.
(28 October 2020)
EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
Translational Lung Cancer Research
2020;
9
(5)
:1720-1723
.
(28 October 2020)
Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
Translational Lung Cancer Research
2020;
9
(5)
:1724-1727
.
(28 October 2020)
Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
Translational Lung Cancer Research
2020;
9
(5)
:1728-1731
.
(28 October 2020)
Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined
Translational Lung Cancer Research
2020;
9
(5)
:1732-1735
.
(28 October 2020)
Original Article
Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care
Translational Lung Cancer Research
2020;
9
(5)
:1736-1748
.
(28 October 2020)
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(5)
:1749-1758
.
(28 October 2020)
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples
Translational Lung Cancer Research
2020;
9
(5)
:1759-1769
.
(28 October 2020)
The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis
Translational Lung Cancer Research
2020;
9
(5)
:1770-1784
.
(28 October 2020)
Treatments for combined small cell lung cancer patients
Translational Lung Cancer Research
2020;
9
(5)
:1785-1794
.
(28 October 2020)
Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(5)
:1795-1809
.
(28 October 2020)
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(5)
:1810-1821
.
(28 October 2020)
Significant diaphragm elevation suggestive of phrenic nerve injury after thoracoscopic lobectomy for lung cancer: an underestimated problem
Translational Lung Cancer Research
2020;
9
(5)
:1822-1830
.
(28 October 2020)
Interactions between the enhanced recovery after surgery pathway and risk factors for lung infections after pulmonary malignancy operation
Translational Lung Cancer Research
2020;
9
(5)
:1831-1842
.
(28 October 2020)
Establishment and validation of a mathematical diagnosis model to distinguish benign pulmonary nodules from early non-small cell lung cancer in Chinese people
Translational Lung Cancer Research
2020;
9
(5)
:1843-1852
.
(28 October 2020)
Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study
Translational Lung Cancer Research
2020;
9
(5)
:1853-1861
.
(28 October 2020)
Stereotactic body radiation therapy for empirically treated hypermetabolic lung lesions: a single-institutional experience identifying the Charlson score as a key prognostic factor
Translational Lung Cancer Research
2020;
9
(5)
:1862-1872
.
(28 October 2020)
Longitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(5)
:1873-1884
.
(28 October 2020)
ACOT11 promotes cell proliferation, migration and invasion in lung adenocarcinoma
Translational Lung Cancer Research
2020;
9
(5)
:1885-1903
.
(28 October 2020)
Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells
Translational Lung Cancer Research
2020;
9
(5)
:1904-1914
.
(28 October 2020)
Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study
Translational Lung Cancer Research
2020;
9
(5)
:1915-1923
.
(28 October 2020)
How long is cessation of preoperative smoking required to improve postoperative survival of patients with pathological stage I non-small cell lung cancer?
Translational Lung Cancer Research
2020;
9
(5)
:1924-1939
.
(28 October 2020)
SMO mutations confer poor prognosis in malignant pleural mesothelioma
Translational Lung Cancer Research
2020;
9
(5)
:1940-1951
.
(28 October 2020)
Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib
Translational Lung Cancer Research
2020;
9
(5)
:1952-1962
.
(28 October 2020)
A pilot study of the ultrathin cryoprobe in the diagnosis of peripheral pulmonary ground-glass opacity lesions
Translational Lung Cancer Research
2020;
9
(5)
:1963-1973
.
(28 October 2020)
Enumeration and molecular characterization of circulating tumor cells enriched by microcavity array from stage III non-small cell lung cancer patients
Translational Lung Cancer Research
2020;
9
(5)
:1974-1985
.
(28 October 2020)
Is clinical target volume necessary?—a failure pattern analysis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy using intensity-modulated radiotherapy technique
Translational Lung Cancer Research
2020;
9
(5)
:1986-1995
.
(28 October 2020)
Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy
Translational Lung Cancer Research
2020;
9
(5)
:1996-2007
.
(28 October 2020)
Study Protocol
GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/ unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy
Translational Lung Cancer Research
2020;
9
(5)
:2008-2015
.
(28 October 2020)
Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 cases
Translational Lung Cancer Research
2020;
9
(5)
:2016-2026
.
(28 October 2020)
Technical Note
Dynamic titanium prosthesis based on 3D-printed replica for chest wall resection and reconstruction
Translational Lung Cancer Research
2020;
9
(5)
:2027-2032
.
(28 October 2020)
Review Article
Optimizing current standard of care therapy for stage III non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(5)
:2033-2039
.
(28 October 2020)
A narrative review of toxicity of chemoradiation and immunotherapy for unresectable, locally advanced non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(5)
:2040-2050
.
(28 October 2020)
Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(5)
:2051-2058
.
(28 October 2020)
Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy
Translational Lung Cancer Research
2020;
9
(5)
:2059-2073
.
(28 October 2020)
A narrative review of lung cancer cytology in the times of coronavirus: what physicians should know
Translational Lung Cancer Research
2020;
9
(5)
:2074-2081
.
(28 October 2020)
A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy
Translational Lung Cancer Research
2020;
9
(5)
:2082-2096
.
(28 October 2020)
Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy
Translational Lung Cancer Research
2020;
9
(5)
:2097-2112
.
(28 October 2020)
A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation
Translational Lung Cancer Research
2020;
9
(5)
:2113-2119
.
(28 October 2020)
Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review
Translational Lung Cancer Research
2020;
9
(5)
:2120-2136
.
(28 October 2020)
Perspective on treatment for unresectable locally advanced non-small cell lung cancer with oncogene-driven mutation: a narrative review
Translational Lung Cancer Research
2020;
9
(5)
:2137-2144
.
(28 October 2020)
Case Report
Novel ALK mutation with durable response to brigatinib—a case report
Translational Lung Cancer Research
2020;
9
(5)
:2145-2148
.
(28 October 2020)
Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report
Translational Lung Cancer Research
2020;
9
(5)
:2149-2156
.
(28 October 2020)
A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient
Translational Lung Cancer Research
2020;
9
(5)
:2157-2160
.
(28 October 2020)
Editorial Commentary
New fissure-attached nodules in lung cancer screening: more practical implications from the NELSON study?
Translational Lung Cancer Research
2020;
9
(5)
:2161-2164
.
(28 October 2020)
FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression
Translational Lung Cancer Research
2020;
9
(5)
:2165-2172
.
(28 October 2020)
Finding chinks in the osimertinib resistance armor
Translational Lung Cancer Research
2020;
9
(5)
:2173-2177
.
(28 October 2020)
HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(5)
:2178-2183
.
(28 October 2020)
The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(5)
:2184-2187
.
(28 October 2020)
Letter to the Editor
Meningeal metastasis patients with EGFR G724S who develop resistance to osimertinib benefit from the addition of afatinib
Translational Lung Cancer Research
2020;
9
(5)
:2188-2190
.
(28 October 2020)
Editorial on New Developments in Lung Cancer Diagnosis and Pathological Patient Management Strategies1
New developments in lung cancer diagnosis and pathological patient management strategies
Translational Lung Cancer Research
2020;
9
(5)
:2191-2193
.
(28 October 2020)
Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists
Translational Lung Cancer Research
2020;
9
(5)
:2194-2198
.
(28 October 2020)
Review Article on New Developments in Lung Cancer Diagnosis and Pathological Patient Management Strategies1
New insights into the interaction of the immune system with non-small cell lung carcinomas
Translational Lung Cancer Research
2020;
9
(5)
:2199-2213
.
(28 October 2020)
Patient-derived cell line, xenograft and organoid models in lung cancer therapy
Translational Lung Cancer Research
2020;
9
(5)
:2214-2232
.
(28 October 2020)
New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts
Translational Lung Cancer Research
2020;
9
(5)
:2233-2244
.
(28 October 2020)
How should molecular findings be integrated in the classification for lung cancer?
Translational Lung Cancer Research
2020;
9
(5)
:2245-2254
.
(28 October 2020)
A narrative review of digital pathology and artificial intelligence: focusing on lung cancer
Translational Lung Cancer Research
2020;
9
(5)
:2255-2276
.
(28 October 2020)
Primary tumor and metastasis—sectioning the different steps of the metastatic cascade
Translational Lung Cancer Research
2020;
9
(5)
:2277-2300
.
(28 October 2020)
Erratum
Erratum to clinical impact of the lung tissue transcriptome in a teenager with multifocal invasive mucinous adenocarcinoma—a case report
Translational Lung Cancer Research
2020;
9
(5)
:2301
.
(28 October 2020)
Disclosure:
1. The series “New Developments in Lung Cancer Diagnosis and Pathological Patient Management Strategies” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Helmut Popper served as the unpaid Guest Editor for the series.
